According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about DermTech’s business, operations, and prospects. Specifically, defendants failed to disclose to investors that:
- DermTech experienced challenges with collections from commercial payors;
- as a result, there was a lower average selling price for DermTech’s DermTech Melanoma Test (“DMT”);
- as a result of the foregoing, DermTech’s revenue growth would be adversely impacted; and
- as a result of the foregoing, defendants’ positive statements about DermTech’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.